Santoni Matteo, Catanzariti Francesco, Minardi Daniele, Burattini Luciano, Nabissi Massimo, Muzzonigro Giovanni, Cascinu Stefano, Santoni Giorgio
Department of Medical Oncology, Polytechnic University of the Marche Region, 60126 Ancona, Italy.
Adv Urol. 2012;2012:397412. doi: 10.1155/2012/397412. Epub 2012 Jul 2.
Transitional cell carcinoma (TCC) of the bladder is one of the most common malignancies of genitourinary tract. Patients with bladder cancer need a life-long surveillance, directly due to the relatively high recurrence rate of this tumor. The use of cystoscopy represents the gold standard for the followup of previously treated patients. Nevertheless, several factors, including cost and invasiveness, render cystoscopy not ideal for routine controls. Advances in the identification of specific alterations in the nuclear structure of bladder cancer cells have opened novel diagnostic landscapes. The members of nuclear matrix protein family BLCA-1 and BLCA-4, are currently under evaluation as bladder cancer urinary markers. They are involved in tumour cell proliferation, survival, and angiogenesis. In this paper, we illustrate the role of BLCA-1 and BLCA-4 in bladder carcinogenesis and their potential exploitation as biomarkers in this cancer.
膀胱移行细胞癌(TCC)是泌尿生殖道最常见的恶性肿瘤之一。膀胱癌患者需要终身监测,这直接归因于该肿瘤相对较高的复发率。膀胱镜检查是对先前治疗患者进行随访的金标准。然而,包括成本和侵入性在内的几个因素,使得膀胱镜检查对于常规检查并不理想。在识别膀胱癌细胞核结构的特定改变方面取得的进展开辟了新的诊断前景。核基质蛋白家族成员BLCA-1和BLCA-4目前正在作为膀胱癌尿液标志物进行评估。它们参与肿瘤细胞的增殖、存活和血管生成。在本文中,我们阐述了BLCA-1和BLCA-4在膀胱癌发生中的作用及其作为该癌症生物标志物的潜在应用。